Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.35M | 0.00 | 0.00 | 881.71K | 3.94M | 36.14M | Gross Profit |
850.12K | -31.17M | -1.49M | -757.53K | 3.84M | 36.05M | EBIT |
-46.22M | -45.08M | -39.84M | -55.99M | -122.81M | -77.10M | EBITDA |
-41.82M | -44.44M | -38.73M | -54.97M | -121.69M | -76.37M | Net Income Common Stockholders |
-38.70M | -44.60M | -55.83M | -45.55M | -111.30M | -69.15M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
41.75M | 20.91M | 59.20M | 97.65M | 85.43M | 31.75M | Total Assets |
46.99M | 28.27M | 66.31M | 107.73M | 102.29M | 49.14M | Total Debt |
394.31K | 20.88M | 25.09M | 26.59M | 26.84M | 9.45M | Net Debt |
-41.35M | 7.16M | 8.09M | 1.58M | -58.60M | -22.30M | Total Liabilities |
19.47M | 35.18M | 33.32M | 38.62M | 57.02M | 42.98M | Stockholders Equity |
27.52M | -6.90M | 32.99M | 69.11M | 45.27M | 6.16M |
Cash Flow | Free Cash Flow | ||||
-36.86M | -36.10M | -37.56M | -48.24M | -100.17M | -48.46M | Operating Cash Flow |
-36.86M | -36.10M | -37.54M | -48.18M | -99.69M | -45.72M | Investing Cash Flow |
-119.65M | 35.64M | 30.07M | -73.42M | -484.49K | -2.74M | Financing Cash Flow |
164.69M | -2.82M | -533.62K | 60.82M | 154.87M | 38.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $4.10B | 22.72 | 81.65% | ― | 63.39% | ― | |
66 Neutral | $1.57B | ― | -9.85% | ― | 56.60% | -403.56% | |
59 Neutral | $537.90M | ― | -182.71% | ― | 432.03% | 14.41% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
46 Neutral | $421.09M | ― | 91.25% | ― | -12.26% | 32.86% | |
32 Underperform | $83.79M | ― | -51.32% | ― | ― | 58.00% |
Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.
On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.